Agios to Present IDH Program Insights at Tumor Metabolism Keystone Symposia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 22, 2013 - Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that Katharine Yen, Ph.D., director, biology, will present insights into the company's lead isocitrate dehydrogenase (IDH) program at the Tumor Metabolism Keystone Symposia being held February 24-March 1, 2013 in Keystone, Colo.
“This symposia is comprised of leading experts in cancer cell metabolism, including the founders of Agios, who have pioneered key advances in the field,” said Scott Biller, Ph.D., chief scientific officer. “We are delighted to be a part of this forum. The audience, along with our fellow session speakers, creates an ideal environment to discuss progress in the overall field and share updates on our IDH program.”
The schedule for Agios' presentations is as follows:
|Date & Time:
|Thursday, February 28, 2013 at 3:00 p.m. (MST)|
|Tumor Metabolism (X4) Workshop 2: Novel Therapeutic Approaches|
|Katharine Yen, Ph.D., director, biology|
|Thursday, February 28, 2013 at 5:00 p.m. (MST)|
|Influence of Metabolism on Epigenetic Regulation|
Selective IDH Inhibitors Mediate Histone and DNA Methylation
|Katharine Yen, Ph.D.,
In addition, Agios founders Craig B. Thompson, M.D., Memorial Sloan-Kettering Cancer Center; Tak W. Mak, Ph.D., Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital; and Lewis C. Cantley, Ph.D., Weill Cornell Medical College, will participate in various sessions during the symposia. Dr. Thompson will also serve as the keynote speaker for the meeting on Tumor Metabolism.
About Agios Pharmaceuticals, Inc.
Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.
Contact: Agios Pharmaceuticals, Inc.
Dan Budwick, 973-271-6085
Posted: February 2013